Skip to main content

Adicet Bio to Participate in a Fireside Chat at the Guggenheim 2nd Annual Healthcare Innovation Conference

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the Guggenheim 2nd Annual Healthcare Innovation Conference being held from November 10-12, 2025 in Boston.

Details of the event are as follows:

Date: Tuesday, November 11, 2025

Time: 3:00 p.m. ET

The live audio webcast can be accessed on the Investors section of Adicet Bio’s website at http://www.adicetbio.com. An archived replay will be available for 30 days following the presentation.

About Adicet Bio, Inc.

Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit our website at https://www.adicetbio.com.

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  245.72
+4.16 (1.72%)
AAPL  257.19
-3.14 (-1.21%)
AMD  204.62
-5.40 (-2.57%)
BAC  56.49
+0.85 (1.54%)
GOOG  327.44
+5.00 (1.55%)
META  643.30
-5.39 (-0.83%)
MSFT  478.30
-5.17 (-1.07%)
NVDA  184.34
-4.78 (-2.52%)
ORCL  190.43
-2.41 (-1.25%)
TSLA  436.53
+5.12 (1.19%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.